The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial von Jurgens, M. S., Safy-Khan, M., de Hair, M. J. H., Bijlsma, J. W. J., Welsing, P. M. J., Tekstra, J., Lafeber, F. P. J. G., Sasso, E. H., Jacobs, J. W. G.

Volltext

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if oste... von van der Goes, M. C., Jacobs, J. W. G., Jurgens, M. S., Bakker, M. F., van der Veen, M. J., van der Werf, J. H., Welsing, P. M. J., Bijlsma, J. W. J.

Volltext

The separate impact of tight control schemes and disease activity on quality of life in patients with early rheumatoid arthritis: results from the CAMERA trials von Jurgens, M S, Welsing, P M J, Geenen, R, Bakker, M F, Schenk, Y, de Man, Y A, Bijlsma, J W J, Lafeber, F P J G, Jacobs, J W G

Volltext

The use of conventional disease-modifying anti-rheumatic drugs in established RA von Jurgens, M.S., MSc, Jacobs, J.W.G., MD, PhD, Bijlsma, J.W.J., MD, PhD

Volltext

AB0184 Applying the conrew score to camera -trial ii data von Jurgens, M. S., vd Goes, M. C., Bakker, M. F., Welsing, P. M., Boers, M., Bijlsma, J. W., Lafeber, F. P., Jacobs, J. W.

Volltext

SAT0060 Tight Control Schedules Could be a Burden to Patients with Early RA, but they do not Negatively Impact the Improved Quality of Life Via Decreased Disease Activity - Results... von Jurgens, M. S., Welsing, P. M., Geenen, R., Bakker, M. F., Schenk, Y., de Man, Y. A., Bijlsma, J. W., Lafeber, F. P., Jacobs, J. W.

Volltext

THU0594 Improved Psychological Well-Being and Physical Functioning in Rheumatoid Arthritis: A Cohort Study Covering Two Decades von Overman, C. L., Verhoef-Jurgens, M. S., Welsing, P. M., Bossema, E. R., Jacobs, J. W., Bijlsma, J. W., Geenen, R.

Volltext

The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial von Jurgens, M. S, Safy-Khan, M, De Hair, M. J.H, Bijlsma, J. W.J, Welsing, P. M.J, Tekstra, J, Lafeber, F. P.J.G, Sasso, E. H, Jacobs, J. W.G

Volltext

Emergency department preparedness for the evaluation and treatment of victims of biological or chemical terrorist attack von Greenberg, Michael I, Jurgens, Sherri M, Gracely, Ed J

Volltext

Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission von Jurgens, Maud S, Welsing, Paco M J, Jacobs, Johannes W G

Volltext

FRI0079 Response to mtx plus prednisone in camera ii using a multi-biomarker disease activity test (vectra™ da) and das28-esr von Jurgens, M. S., Bijlsma, J. W., Jacobs, J. W., Bakker, M. F., Lafeber, F. P., Welsing, P. M., Cavet, G., Chernoff, D. N., Sasso, E. H., Li, W., Haney, D. J.

Volltext

FRI0079 Response to mtx plus prednisone in camera ii using a multi-biomarker disease activity test (vectra(TM) da) and das28-esr von Jurgens, M S, Bijlsma, J W, Jacobs, J W, Bakker, M F, Lafeber, F P, Welsing, P M, Cavet, G, Chernoff, D N, Sasso, E H, Li, W, Haney, D J

Volltext

Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission: Treat-to-target in Rheumatoid Arthritis: Clinical and Pharmacoeconomic Consideration... von JURGENS, M. S, WELSING, P. M. J, JACOBS, J. W. G

Volltext

AB0405 No decrease in bone mineral density when prednisone is added to a methotrexate-based tight control strategy for early rheumatoid arthritis von van der Goes, M.C., Jacobs, J.W., Jurgens, M.S., Bakker, M.F., Welsing, P.M., Bijlsma, J.W.

Volltext

FRI0024 Contribution of the Individual Components of the Disease Activity Score (DAS28) to the Total DAS28 Score among Responders and Non-Responders to Biological Therapy for Rheum... von Jurgens, M.S., Overman, C.L., Jacobs, J.W., Geenen, R., Cuppen, B.V., Marijnissen, A.C., Bijlsma, J.W., Welsing, P.M., Lafeber, F.P., van Laar, J.M.

Volltext

A10.22 Response to MTX Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (Vectra™DA) TEST and DAS28-ESR von Bijlsma, JWJ, Jurgens, MS, Jacobs, JWG, Bakker, M, Lafeber, FPJ, Welsing, PMJ, Cavet, G, Chernoff, D, Sasso, EH, Li, W, Haney, DJ

Volltext

A10.22 Response to MTX Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (Vectra(TM)DA) TEST and DAS28-ESR von Bijlsma, JWJ, Jurgens, MS, Jacobs, JWG, Bakker, M, Lafeber, FPJ, Welsing, PMJ, Cavet, G, Chernoff, D, Sasso, EH, Li, W, Haney, DJ

Volltext

Evinacumab for Homozygous Familial Hypercholesterolemia von Raal, Frederick J, Rosenson, Robert S, Reeskamp, Laurens F, Hovingh, G. Kees, Kastelein, John J.P, Rubba, Paolo, Ali, Shazia, Banerjee, Poulabi, Chan, Kuo-Chen, Gipe, Daniel A, Khilla, Nagwa, Pordy, Robert, Weinreich, David M, Yancopoulos, George D, Zhang, Yi, Gaudet, Daniel

Volltext

AB0408 Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis (CAMERA-II): Is it a side-effect of the prednison... von Jurgens, M.S., Jacobs, J.W., Geenen, M.M., Bossema, E.R., Bakker, M.F., Bijlsma, J.W., van Albada-Kuipers, G.A., Ehrlich, J.C., Lafeber, F.P., Welsing, P.M.

Volltext

ACR Appropriateness Criteria Headache von Douglas, Annette C., MD, Wippold, Franz J., MD, Broderick, Daniel F., MD, Aiken, Ashley H., MD, Amin-Hanjani, Sepideh, MD, Brown, Douglas C., MD, Corey, Amanda S., MD, Germano, Isabelle M., MD, Hadley, James A., MD, Jagadeesan, Bharathi D., MD, Jurgens, Jennifer S., MD, Kennedy, Tabassum A., MD, Mechtler, Laszlo L., MD, Patel, Nandini D., MD, Zipfel, Gregory J., MD

Volltext